leadf
logo-loader
viewRevive Therapeutics

Revive Therapeutics commits to 10 sites for Phase 3 coronavirus trial of bucillamine

The study is testing two dosage levels of bucillamine, and an interim analysis of the initial patients will determine the better performing dose arm for the remainder of the trial

Coronavirus graphic
The trial will enroll as many as 1,000 patients that will be randomized 1:1:1 to receive bucillamine 100 mg three times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) announced Monday that it has committed to 10 clinical sites in the US for its Phase 3 trial of bucillamine in mild-to-moderate cases of the coronavirus and expects more than 200 patients to complete the study by the end of the year. 

The study is testing two dosage levels of bucillamine, and an interim analysis of the initial patients will determine the better performing bucillamine dose arm for the remainder of the trial and future complementary studies of more severe cases.

“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the US, we are confident that our targets will be achieved to support the potential FDA approval and commercialization of bucillamine for the treatment of the virus,” CEO Michael Frank said in a statement.

READ: Revive Therapeutics signs supply agreement with Havn Life Sciences to source psychedelic compounds for use in future studies

The trial, titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll as many as 1,000 patients that will be randomized 1:1:1 to receive bucillamine 100 mg three times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days. 

The company also pointed to the recent publication of research in the October 2020 issue of Clinical Immunology highlighting the potential of N-acetyl-cysteine (NAC) in the treatment of COVID-19. NAC has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione. Revive said the research serves as further validation for bucillamine as a potential COVID-19 treatment.

Bucillamine, with its well-established safety record in more than 30 years of use in the treatment of rheumatoid arthritis, has been shown to be 16 times more potent as a thiol donor in vivo than NAC. Bucillamine also has the potential to lessen the destructive consequences of more advanced SARS-CoV-2 infections, the company said.

The company added that it is not making any express or implied claims that its product has the ability to eliminate or cure the coronavirus at this time.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Revive Therapeutics

Price: 0.285 CAD

CSE:RVV
Market: CSE
Market Cap: $67.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read